Innoviva Inc reports results for the quarter ended March 31 - Earnings Summary

• Innoviva Inc INVA.OQ reported a quarterly adjusted loss of 74 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 46 cents. The lone analyst forecast for the quarter was for earnings of 29 cents per share.

• Revenue rose 14.4% to $88.63 million from a year ago; analysts expected $82.67 million.

• Innoviva Inc shares had risen by 3.2% this quarter and gained 7.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 23.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Innoviva Inc is $55.00

This summary was machine generated from LSEG data May 7 at 09:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)